Beverly A. Teicher

This study screens combinations of RAS pathway inhibitors with targeted agents in patient-derived spheroids with KRAS variants, identifying effective combinations that reduce viability.

This study shows that LMNA deficiency in SCLC increases R-loop accumulation, leading to genomic instability and poor patient survival.

The paper evaluates combinations of apoptosis pathway inhibitors with other agents in multi-cell type tumor spheroids to identify effective therapeutic strategies.

This study identifies DLK1 as a potential immunotherapeutic target in neuroblastoma through integrative proteomic, transcriptomic, and epigenomic analysis.

The paper identifies RB1 WT SCLC cell lines and finds some are sensitive to CDK4/6 inhibition.